① 연구실명 : RNA 치료 및 정밀 의학 연구실(RNA-therapeutics and Precision Medicine Lab)
② 지도교수명 : 전영준 교수(Prof. Jeon, Young-Jun)
③ 연구실 소개
안녕하세요, 저희는 성균관대학교 생명공학대학 융합생명공학과 전영준 교수님 'RNA 치료 및 정밀 의학 연구실' 입니다. 저희는 주로 암 세포 생물학과 차세대 염기서열 분석 및 생명정보학적 방법을 이용하여 항암 치료 및 저항기전을 연구하며, 의과대학과 협업하여 관련 내용을 액체생검 방식을 이용하여 환자 수준에서 확인하는 이른바 정밀의학을 연구하는 lab입니다. 졸업 후 의.약학 연구 기반의 연구실이나, 회사등으로 진출합니다. 저희 연구실의 대표 전화는 031-290-7862이며 이메일 주소는 jeon2020@skku.edu이오니 관심있는 분들께서는 언제든 연락주시기 바랍니다. 감사합니다.
"RNA-theraputics & Precision Medicine (RPM)" is a newly established laboratory in the department of Integrative Biotechnology, Sungkyunkwan University. The overarching goal of our research team is to develop a better understanding of cancer progression mainly focusing on therapeutics using transcriptomic approaches with invasive and/or non-invasive method. We employ cancer cell biology, tools of genomics and Bioinformatics from pre-processed data sets and cancer tissues / cell lines. Importantly, we aim to apply all this knowledge to patient level by analyzing cell free mRNAs from patient plasma. The projects will be performed on a collaboration basis with Samsung Hospital domestically and Stanford School of Medicine / The Ohio State University School of Medicine internationally. Our alumni are expecting to become an independent researcher working on a university, profit organization / company as well as a research laboratory. Our ultimate goal is to develop a better strategy to treat patients with cancers as a translational approach on the basis of precision medicine.
④ 연구분야
암 정밀 의학 / 항암 치료 및 저항 기전 / 암 세포 생물학 / 액체 생검 / 차세대 염기서열 분석
Precision medicine / Drug resistance / Cancer Cell Biology / Liquid Biopsy / Circulating tumor nucleic acids / NGS
⑤ 대표연구 실적
■ Jeon YJ*, Binkely MS*, …. Diehn M. KEAP1/NFE2L2 mutations predict high risk for local recurrence after radiation therapy but not surgery in non-small cell lung cancer. *Equal Contribution Cancer Discovery, in-revision with minor comments, Impact factor - 29.497
■ Nabet BY*, Eshfahani MS*, ….Jeon YJ…. Alizadeh AA# and Diehn M#. A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint blockade for lung cancer. Cell, in-revision
■ Chabon JJ*, Hamilton EG*, Kurtz DM*, Esfahani MS*…., Jeon YJ…., Alizadeh AA and Diehn M. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020 Apr;580(7802):245-251. doi: 10.1038/s41586-020-2140-0. Epub 2020 Mar 25.
■ Jeon YJ*, Esfahani MS*, Lee L*, …., Alizadeh AA and Diehn M. Functional Significance of U2AF1 S34F Mutations in Lung Adenocarcinoma. Nat Commun. 2019 Dec 13;10(1):5712. doi: 10.1038/s41467-019-13392-y. * Equal contribution, Impact factor - 12.121
■ Jeon YJ*, Kim T*, …., Cui R and Croce CM. miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC. * Equal contribution Nat Commun. 2018 Nov 30;9(1):5110. doi: 10.1038/s41467-018-07561-8. Impact factor - 11.878
■ Jeon YJ, Kim S, Kim JH, Youn UJ and Suh S-S. The Comprehensive Roles of ATRANORIN, A Secondary Metabolite from the Antarctic Lichen Stereocaulon caespitosum, in HCC Tumorigenesis. Molecules. 2019 Apr 10;24(7). pii: E1414. doi: 10.3390/molecules24071414. Impact factor - 3.267
■ Sun HL, …., Jeon YJ, …. Peng Y and Croce CM. ERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5. Cancer Cell. 2016 Nov 14;30(5):723-736. doi: 10.1016/j.ccell.2016.10.001.
■ Jeon YJ*, Joshi P*, …., Croce CM. MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8650-5. doi: 10.1073/pnas.1500886112. * Equal Contribution, Impact factor - 9.423
■ Jeon YJ, …., Garofalo M and Croce CM. A set of NF-κB-regulated microRNAs Induces Acquired TRAIL Resistance in Lung Cancer. Proc Natl Acad Sci U S A. published ahead of print 2015 Jun 15, doi:10.1073/pnas.1504630112. Impact factor - 9.423
■ Jeon YJ*, Kim T*,…., Croce CM. Role of MYC-Regulated Long Noncoding RNAs in Cell Cycle Regulation and Tumorigenesis. J Natl Cancer Inst. 2015 Feb 6;107(4). * Equal Contribution. Impact factor - 11.370
■ Jeon YJ*, Garofalo M*,…., Croce CM. MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. PLoS One. 2013 Jun 21;8(6):e67581. doi: 10.1371/journal.pone.006758 * Equal Contribution. Impact factor - 3.534
■ Jeon YJ*, Kim IK*, …., Jung YK. Ribosomal protein S6 is a selective mediator of TRAIL-apoptotic signaling. Oncogene. 2008 Jul 17;27(31):4344-52. * Equal Contribution. Impact factor - 6.371
⑥ 대표전화 : 031-290-7871
⑦ 위치 : 생명공학관 62동 108호